Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2014; 20(33): 11552-11559
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11552
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11552
Metachronous gastric cancer after successful Helicobacter pylori eradication
Akiko Shiotani, Ken Haruma, Department of Internal Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan
David Y Graham, Department of Medicine, Michael E DeBakey VAMC and Baylor College of Medicine, Houston, TX 77030, United States
Author contributions: Shiotani A mainly wrote the manuscript; Haruma K and Graham DY edited the manuscript.
Correspondence to: Akiko Shiotani, MD, PhD, Department of Internal Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Japan. shiotani@med.kawasaki-m.ac.jp
Telephone: +81-86-4621111 Fax: +81-86-4641195
Received: October 25, 2013
Revised: December 30, 2013
Accepted: May 28, 2014
Published online: September 7, 2014
Processing time: 313 Days and 18.4 Hours
Revised: December 30, 2013
Accepted: May 28, 2014
Published online: September 7, 2014
Processing time: 313 Days and 18.4 Hours
Core Tip
Core tip: For the patients with a history of endoscopic resection of early gastric cancer, Helicobacter pylori (H. pylori) eradication followed by continued surveillance for gastric cancer is generally required because those with severe gastric atrophy retain considerable gastric cancer risk even after H. pylori eradication. We review the role of H. pylori and effect of H. pylori eradication indicating the incidence and the predictive factors on development of metachronous cancer after endoscopic therapy of early gastric cancer.